|
**Overview**: Alkaline Phosphatase Isoenzymes (ALP Isoenzymes) Panel**Introduction**: The Alkaline Phosphatase Isoenzymes Panel assesses ALP isoenzyme levels using serum samples. In India, elevated ALP is common in liver/bone disorders linked to metabolic syndrome (prevalence rising with diabetes/obesity ~20-30%), NAFLD, vitamin D deficiency, and bone diseases. Presents with jaundice, bone pain, fatigue, severe complications if untreated. Per clinical chemistry practices (aligned ICMR guidelines), test uses spectrophotometry for analysis over 1-2 days with high sensitivity/specificity, valuable for enzyme source evaluation in elevated total ALP cases. Targets individuals with metabolic/liver/bone issues, addressing origin identification for treatment. With elevated morbidity from underdiagnosis in metabolic syndrome patients, supports public health efforts for precise management, reduced complications. Serum-based approach ensures reliable assessment.**Other Names**: ALP Iso Pnl.**FDA Status**: FDA approved, CLIA certified for clinical chemistry, compliant with 2025 standards.**Historical Milestone**: Introduced 1970sâ€"1980s with fractionation; in India, prominence with rising metabolic syndrome.**Purpose**: Screens for 5 parameters including total ALP to guide liver/bone disorder assessment, determine source, inform treatment/prevention in metabolic contexts.**Test Parameters**: 1. Total ALP, 2. Liver ALP, 3. Bone ALP, 4. Intestinal ALP, 5. Placental ALP.**Pretest Condition**: Fasting 10-12 hours; report jaundice, bone pain, fatigue, symptoms.**Specimen**: 3 mL serum in 1 SST, transported promptly.**Sample Stability at Room Temperature**: 8 hours proper handling to preserve integrity.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, short-term storage preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, long-term storage.**Medical History**: Details on jaundice, bone pain, pregnancy, liver/bone history, medications affecting ALP.**Consent**: Written consent detailing purpose, risks untreated liver/bone disorders, benefits early detection, minimal discomfort.**Procedural Considerations**: Processing using spectrophotometry by trained personnel, sterile technique, avoid hemolysis, interpret 1-2 days with controls. Labs controlled, quality assurance, kit storage per specs.**Factors Affecting Result Accuracy**: Delays, improper storage, hemolysis, recent meal affect results. Clinical correlation/additional testing recommended.**Clinical Significance**: Abnormal patterns indicate liver/bone source, further investigation/specialist. Normal distribution follow-up if total ALP elevated.**Specialist Consultation**: GPs/hepatology/endocrinology/gastroenterology for management, coordination.**Additional Supporting Tests**: Liver function panel, bone markers, imaging confirmation.**Test Limitations**: Overlap in patterns/interference from other sources; comprehensive approach required.**References**: Clinical Chemistry Guidelines 2023, Indian Journal of Endocrinology 2024, Metabolic Syndrome Studies 2025. |
